|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we engineered tumor-targeted CAR T cells to constitutively express the immune-stimulatory molecule CD40 ligand (CD40L) and explored efficacy in different mouse leukemia/lymphoma models.
|
30889381 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration.
|
28771100 |
2017 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
B-cell receptor engagement by auto-antigen as well as T-cell help including both cognate interaction and bystander help via soluble ligands such as CD40L and BAFF are thought to underpin the immunological drive in the lymphoma development through activation of the canonical and non-canonical NF-κB pathway respectively.
|
27452667 |
2016 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.
|
25382101 |
2015 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that single nucleotide polymorphisms (SNPs) in TNFRSF5 and TNFSF5 encoding the CD40 and CD154 proteins, respectively, influence lymphoma risk, particularly a functional TNFRSF5 SNP (-1C>T, rs1883832) associated with reduced B-cell CD40 expression.
|
18287517 |
2008 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD154 (CD40-ligand) is a critical transmembrane molecule with potent immune-stimulatory properties that is used in clinical applications of gene therapy for leukemia and lymphoma.
|
17893562 |
2007 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival.
|
16099873 |
2005 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role.
|
15360007 |
2004 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection of A20 B lymphoma cells with a replication-defective adenovirus encoding murine (m) CD40L, but not mIL-2, produces an antigen presentation phenotype with upregulation of MHC Class I/II, induction of B7-1/2 molecules and production of MIL-12 and MIP-1alpha.
|
15300803 |
2004 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed an upregulation of the TNFR apoptosis-inducing ligand Fas, and in contrast to CD40L-induced protection, an enhancement of lymphoma sensitivity to Fas-induced apoptosis.
|
14562115 |
2003 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we introduce our two kinds of CD40 ligand immuno-genetherapy; (1) oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium (published in BLOOD 2000), (2) cancer vaccine transfected with CD40 ligand ex vivo for neuroblastoma (unpublished).
|
11911421 |
2002 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium.
|
10666198 |
2000 |